{"contentid": 488696, "importid": NaN, "name": "Double dose of COVID-19 vaccine approvals in Japan", "introduction": "With the Olympic Games just a couple of months away and coronavirus cases in the country at a dangerous point, Japan has approved two vaccines in a single day.", "content": "<p>With the Olympic Games just a couple of months away and coronavirus cases in the country at a dangerous point, Japan has approved two vaccines in a single day.</p>\n<p>AstraZeneca&rsquo;s (LSE: AZN) Vaxzevria (ChAdOx1-S [recombinant]), formerly AZD1222, has been granted a special approval for emergency use, as has Moderna&rsquo;s (Nasdaq: MRNA) mRNA COVID-19 vaccine, TAK-919, now known as COVID-19 Vaccine Moderna Intramuscular Injection.</p>\n<h2>'Urgent need'</h2>\n<p>Mene Pangalos, executive vice president, BioPharmaceuticals R&amp;D, AstraZeneca, said: &ldquo;We continue to expand global access to our vaccine and today&rsquo;s approval brings us one step closer to providing Vaxzevria to the people of Japan who urgently need protection from coronavirus.</p>\n<p>&ldquo;We are proud to have produced a vaccine for the world, which is playing a leading role in the global fight against the pandemic, with more than 400 million doses now supplied by AstraZeneca and sub-licensees to 165 countries.&rdquo;</p>\n<p>Production of the vaccine in Japan is already underway, and the first doses are expected to be available in the coming weeks.</p>\n<p>Unlike mRNA-based vaccines, Vaxzevria can be stored, transported and handled at normal refrigerated conditions for at least six months, and administered within existing healthcare settings.</p>\n<h2>Takeda leading the fight in Japan</h2>\n<p>Meanwhile, Takeda (TYO:4502) will immediately begin distribution of the Moderna vaccine in Japan, having carried out an immunogenicity and safety clinical trial of the jab in the country.</p>\n<p>Rajeev Venkayya, president of the Global Vaccine Business Unit at Takeda, said: &ldquo;This is an important step in Takeda&rsquo;s support of Japan&rsquo;s pandemic response.</p>\n<p>&ldquo;Moderna&rsquo;s vaccine has demonstrated an excellent safety and effectiveness profile to date, and we are excited to make it available to the Japanese population.&rdquo;</p>\n<p>The approval is the result of a three-way agreement announced in October 2020 with Moderna and Japan&rsquo;s Ministry of Health Labor and Welfare to distribute 50 million doses of TAK-919 in Japan in the first half of 2021.</p>\n<p>Takeda has also entered into a collaboration with Novavax (Nasdaq: NVAX) to develop, manufacture and commercialize its COVID-19 vaccine candidate in Japan.</p>", "date": "2021-05-21 12:08:00", "meta_title": NaN, "meta_keywords": "vaccine, Japan, months, vaccines, coronavirus, country, dose, Vaxzevria, Double, approvals, couple, cases, dangerous, point, approved, Games, single, Taked", "meta_description": "With the Olympic Games just a couple of months away and coronavirus cases in the country at a dangerous point, Japan has approved two vaccines in a single day.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-21 12:01:20", "updated": "2021-05-21 12:30:37", "access": NaN, "url": "https://www.thepharmaletter.com/article/double-dose-of-vaccine-approvals-in-japan", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "japan-mount-fuji-large-1-.jpg", "image2id": "japan-mount-fuji-small-1-.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Infectious diseases, Vaccines", "topic_tag": "Asia Pacific, Coronavirus, Focus On, Regulation", "geography_tag": "Japan, Sweden, UK, USA", "company_tag": "AstraZeneca, Takeda", "drug_tag": "COVID-19 Vaccine Moderna, Vaxzevria", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-21 12:08:00"}